Regeneron Pharmaceuticals (REGN) Other Accumulated Expenses (2010 - 2020)

Regeneron Pharmaceuticals' Other Accumulated Expenses history runs 10 years deep, the most recent figure standing at $122.4 million for Q4 2020.

• On a quarterly basis, Other Accumulated Expenses rose 44.0% year-over-year to $122.4 million in Q4 2020; TTM through Dec 2020 was $122.4 million, a 44.0% increase from a year earlier, with the FY2020 full-year figure at $122.4 million, up 44.0% from the prior year.
• Other Accumulated Expenses rose to $122.4 million in Q4 2020 per REGN's latest filing, from $96.9 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $122.4 million in Q4 2020 and bottomed at $267000.0 in Q4 2017.
• The 4-year median for Other Accumulated Expenses is $3.7 million (2016), against an average of $39.8 million.
• Across the five-year window, Other Accumulated Expenses jumped 518.22% in 2016 and sank 93.51% in 2017, its largest moves.
• Year by year, Other Accumulated Expenses stood at $1.2 million in 2016, then sank by 77.33% to $267000.0 in 2017, then surged by 31735.21% to $85.0 million in 2019, then surged by 44.0% to $122.4 million in 2020.
• Per Business Quant, the three latest REGN Other Accumulated Expenses figures stand at $122.4 million (Q4 2020), $96.9 million (Q3 2020), and $103.8 million (Q2 2020).